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Hypophosphatemic rickets is a rare, renal phosphate wasting disorder that 
presents various skeletal deformities. Although there are specific clinical presentations 
and biochemical findings used to identify hypophosphatemic rickets, there are various 
underlying renal phosphate wasting disorders that can lead to hypophosphatemic rickets 
making diagnosis extremely difficult. A targeted literature review through electronic 
search engines (e.g., BMC, PubMed, Google Scholar) was conducted to: 1) consolidate 
and summarize currently available data regarding the various renal phosphate wasting 
disorders, 2) identify current obstacles of successful diagnosis and treatment, and 3) 
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Rickets is a disorder characterized by the softening and weakening of bone due to 
osteomalacia, which is the deficiency of bone mineralization (Allgrove & Shaw, 2015). 
Poor bone mineralization often leads to skeletal deformities that include bowed legs, 
protruded sternum, and thickened wrists and ankles. Vitamin D deficiency is primarily 
attributed to rickets development due to its role in bone mineralization and maintaining 
calcium and phosphate homeostasis. Clinical studies in the 1930s and 1940s revealed 
hereditary genetic disorders as an additional source for the development of rickets 
(Albright, Butler, & Bloomberg, 1937; Albright & Reifenstein Jr, 1949). These 
discoveries led to the identification of insufficient reabsorption of phosphate by the 
proximal renal tubule and increased urinary phosphate excretion as the physiological 
cause for poor bone mineralization, which coined the term hypophosphatemic rickets. 
Despite these research advancements of hypophosphatemic rickets, clinical 
presentations and biochemical findings used to identify hypophosphatemic rickets are 
similar across the various underlying phosphate wasting disorders. The focus of this 
targeted literature review through electronic search engines (e.g., BMC, PubMed, Google 
Scholar) is to: 1) consolidate and summarize currently available data regarding the 
various renal phosphate wasting disorders, 2) identify current obstacles of successful 
diagnosis and treatment, and 3) propose directions for future hypophosphatemic rickets 
research into new biomarkers. 
Bone Development 
 The fully developed, adult human skeleton is comprised of 213 bones, each of 
which is composed of osteoblasts, osteocytes, osteoclasts, osteoids, and inorganic mineral 
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salts deposited within the bone matrix (Rosen, & Bouillon, 2013). Osteoblasts are 
responsible for bone synthesis and mineralization during initial formation by forming a 
closely packed sheet on the surface of the bone, from which cellular processes extend 
through the developing bone. Osteoblasts produce several cell products, including the 
enzymes such as alkaline phosphatase (ALP) and collagenase, as well as hormones like 
osteocalcin and collagen. These cellular products make up the organic, unmineralized 
component of the bone referred to as the osteoid. When the osteoblast is coated by the 
surrounding bone matrix it secretes, it calcifies and becomes a bone cell, also known as 
an osteocyte (Rosen, & Bouillon, 2013). 
Osteocytes are mature bone cells located within fully formed bone. Small 
channels called canaliculi extend from osteocytes to other osteocytes in order to maintain 
bone viability by exchanging nutrients and waste products. Signaling between osteocytes 
is important for bone remodeling (bone metabolism), where mature bone tissue is 
removed from the skeleton (bone resorption) and new bone tissue is formed 
(ossification). Bone resorption and remodeling are activated when biomechanical forces 
on bone, such as fractures, are sensed by the osteocytes via the canalicular network 
(Noble, 2008). In the presence of a bone fracture, osteocytes function as mechanosensor 
cells that recruit osteoclasts and osteoblasts for the resorption of old bone and formation 
of new bone, respectively. Bone resorption is a complex process in which bone-specific 
macrophages known as osteoclasts break down bone tissue, resulting in the transfer of 
calcium, magnesium, phosphate and collagen into the bone’s extracellular matrix (Rosen, 
& Bouillon, 2013). Bone resorption is critical for the formation of new bone, as 
resorption of old bone must precede the formation or deposition of new bone. 
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The formation of new bone occurs at the osteoid, which is also where bone was 
previously resorbed by osteoclasts. From here, osteoblasts prepare the osteoid for 
mineralization by synthesizing dense, crosslinked collagen to provide bone tensile 
strength. The continuous process of bone remodeling maintains the skeletal structure and 
homeostasis of calcium in the body (Driscoll, 2006). During bone resorption by 
osteoclasts, calcium is also released into the bloodstream and to further support continued 
bone growth and remodeling. Bone remodeling can be triggered to external responses, 
such as deformations of bone due to changes in muscular activity. For example, a long 
bone fracture triggers bone remodeling and new bone formation. 
Role of Vitamin D 
Bone formation is also impacted by the circulating levels of vitamin D, a hormone 
that activates the increased absorption of calcium and phosphate for bone development 
(Holick, 2006). Two major forms of vitamin D found in the human body are vitamin D2 
(ergocalciferol) and vitamin D3 (cholecalciferol). Both forms are biologically inactive 
when absorbed into the body by dietary supplementation or after photobiogenesis with 
ultraviolet radiation via sun exposure. Both forms of vitamin D are then hydroxylated by 
25-hydroxyvitamin D3 1-alpha-hydroxylase (1α-hydroxylase) in the liver and kidneys to 
become biologically active. Specifically, ergocalciferol is converted to 25-
hydroxyergocalciferol in the liver, and then to the active form, 1,25-dihydroxyvitamin D, 
in the kidney (Wang, Zhu, & DeLuca, 2012). Once transformed, it binds to the vitamin D 
receptor (VDR), which leads to a variety of regulatory roles (Norman, 2008). 
Cholecalciferol is converted into calcifediol (25-hydroxycholecalciferol) in the liver, and 
calcifediol is further hydroxylated in the kidneys to form calcitriol (1,25-
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dihydroxycholecalciferol), which is the biologically active form of vitamin D (Figure 1) 
(DeLuca, Holick, Schnoes, Suda, & Cousins, 1971; Gil, Plaza-Diaz, & Mesa, 2018; 
Norman, 2008; Silva & Furlanetto, 2018).  
 
 
Figure 1 Depiction of vitamin D structures, process of photobiosynthesis, and process of 
activation (A) Two major forms of vitamin D found in the human body are vitamin D2 
(ergocalciferol) and vitamin D3 (cholecalciferol). (B) 7-dehydrocholesterol is an 
unsaturated sterol found in the epidermis that absorbs ultraviolet radiation via sun exposure 
inducing photoisomerization into previtamin D3, which undergoes spontaneous 
isomerization into cholecalciferol. (C) Vitamin D3 is hydroxylated in the liver by 
cholecalciferol 25-hydroxylase into 25(OH)D3 (calcifediol), which is further hydroxylated 




Calcitriol plays a significant role in the regulation and maintenance of serum 
calcium levels. Calcium is an essential nutrient for bone formation and is found as 
calcium hydroxyapatite in bones and teeth, where it provides structural strength (Ross et 
al., 2010). Although calcium can be provided by food and supplements, bone tissue 
serves as a major source of calcium for bone remodeling. Calcitriol binds to the VDR, 
and the ligand-receptor complex within the nucleus activates the transcription of 
calbindin-D28k, a calcium-binding protein that regulates calcium transport across the 
intestinal mucosa and into the blood increases (Voet & Voet, 2004). VDR is located 
within various cells and tissues including the osteoblasts, epithelial cells, intestine, and 
the kidneys. As a result of this, calcitriol is important for increasing calcium absorption in 
the gastrointestinal tract, increasing renal tubular absorption, and stimulating calcium 
release from bones (Breslau, McGuire, Zerwekh, Frenkel, & Pak, 1984).  
Calcium metabolism is regulated by the parathyroid hormone (PTH), a hormone 
secreted by the parathyroid glands in response to low serum calcium levels. PTH binds to 
the parathyroid hormone 1 receptor (PTHR1) to stimulate osteoclast and osteoblast 
activity in bone to release calcium into the blood (Poole & Reeve, 2005). PTHR1 is 
expressed at high levels in the osteoblasts, and when activated, osteoblasts express 
Receptor Activator of Nuclear Factor kB Ligand (RANKL) (Wada, Nakashima, Hiroshi, 
& Penninger, 2006). RANKL is expressed in several tissues and organs such as the 
skeletal muscle, liver, colon, small intestine, adrenal gland, and osteoblast. RANKL binds 
to its cognate receptor, RANK, which is located on the osteoclast to stimulate bone 
resorption (Wada et al., 2006). This regulates the differentiation of precursor cells into 
multinucleated osteoclasts and osteoclast activation, which is associated with increased 
 6 
 
bone resorption. Other than through the RANKL signaling, PTH also increases serum 
calcium levels by upregulating 1α-hydroxylase production to increase the hydroxylation 
of calcifediol into calcitriol in the kidney (Voet & Voet, 2004). 
Aside from its role in calcium regulation, calcitriol also plays a critical role in 
phosphate reabsorption in the small intestine and kidneys. Phosphate is primarily 
combined with calcium in the form of hydroxyapatite crystals in the skeleton, and this 
helps provide both bone strength and rigidity (Farrow & White, 2010). Serum phosphate 
levels are maintained by intestinal absorption, intracellular and bone storage pool 
exchange, and renal tubular absorption. Approximately 65% of ingested phosphate is 
absorbed in the duodenum and jejunum (Prasad & Bhadauria, 2013). Under the influence 
of calcitriol, phosphate is transported from the small intestine into the blood where it can 
be used for bone deposition and remodeling. Furthermore, circulating phosphate is 
transported into cells via type II and type III sodium-phosphate cotransporters in order to 
complete cellular functions such as deoxyribonucleic acid (DNA) synthesis and 
intracellular signaling (Bergwitz & Jüppner, 2010). Phosphate levels are also regulated 
by the kidneys with phosphate being reabsorbed from urine in the renal proximal tubules 
via type II and type III sodium-phosphate cotransporters with excess phosphate excreted 
in the urine; however, the majority of the phosphate is retained within the bone for bone 
deposition during periods of growth (Rosen, & Bouillon, 2013).  
Calcitriol and phosphate homeostasis is also regulated by fibroblast growth factor 
23 (FGF23), a protein primarily produced by osteocytes, osteoblasts, and osteoclasts 
(Guo & Yuan, 2014). The major roles of FGF23 are: 1) to inhibit renal tubular phosphate 
reabsorption by decreasing Cyp27b1-mediated formation, and 2) suppress circulating 
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calcitriol levels by stimulating Cyp24a1-mediated catabolism of calcitriol (Martin, David, 
& Quarles, 2012). Cyp27b1 and Cyp24a1 are the renal enzymes responsible for calcitriol 
synthesis and calcitriol degradation into calcitroic acid, respectively (Martin et al., 2012). 
As a result of reduced calcitriol levels, phosphate absorption from the intestines into the 
blood is decreased.  
Renal phosphate reabsorption is primarily regulated by feedback loops that 
involve PTH, FGF23, calcitriol, bone and kidney. Regulating phosphate balance in the 
body involves three feedback loops (Figure 2): 1) parathyroid gland produces PTH to 
stimulate phosphate excretion and calcitriol synthesis in kidney; 2) PTH stimulates 
FGF23 and phosphate release following an increase in bone remodeling, where FGF23 
inhibits PTH but phosphate stimulates PTH production; 3) FGF23 in the kidney 
stimulates urinary phosphate excretion and inhibits calcitriol by decreasing 1α-
hydroxylase and increasing 24-hydroxylase activities, both of which are located in the 
kidney and bone. The role of 1α-hydroxylase is to catalyze the hydroxylation of 
calcifediol to calcitriol, while the role of 24-hydroxylase is to catalyze hydroxylation 
reactions leading to the degradation of calcitriol (Rosen, & Bouillon, 2013). Ultimately, 
this leads to reduced serum phosphate and PTH-stimulated calcitriol production, which 





Figure 2 Depiction of the three feedback loops regulating phosphate homeostasis. 
Parathyroid glands produce PTH, which stimulates phosphate excretion and calcitriol 
synthesis in kidneys. Calcitriol in turn lowers phosphate levels and inhibits PTH production 
in parathyroid glands. PTH also stimulates FGF23 production in bone cells and phosphate 
release following increased bone remodeling. In turn, FGF23 inhibits PTH, however 
phosphate stimulates PTH production. FGF23 in the kidneys stimulates urinary phosphate 
excretion and inhibits calcitriol, helping reduce serum phosphate (Torres & De Brauwere, 
2011). 
 
In summary, phosphate is absorbed from that which is provided by dietary intake 
in the gut, stored in bones, and excreted via urine by the kidneys. Calcitriol stimulates 
phosphate absorption from dietary intake. FGF23 increases renal phosphate excretion, 
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suppresses synthesis of calcitriol, and can decrease PTH. PTH increases renal phosphate 
clearance and stimulates synthesis of calcitriol (Torres & De Brauwere, 2011).  
Rickets  
Chronic deficiency in vitamin D or phosphate can result in the development of 
severe skeletal manifestations, with the most prominent being rickets (Rosen, & Bouillon, 
2013). Rickets is a bone condition characterized by weak or soft bones, bone fractures, 
bone pain, stunted growth, skeletal deformities, and, most notably, bowed legs. Rickets is 
more commonly attributed to vitamin D deficiency caused by inadequate sun exposure or 
dietary intake of vitamin D (Table 1) (Holick, 2006). Figure 3 highlights the downstream 
physiological effects of how a vitamin D and calcium deficiency can lead to skeletal 
defects (Holick, 2006).  
Table 1 List of sources causing the clinical manifestation of rickets 
Decreased intestinal absorption Increased urinary excretion 
Vitamin D deficiency or resistance Renal phosphate wasting disorders 
Nutritional deficiency Primary and secondary 
hyperparathyroidism 
Deficient sun exposure Diabetic ketoacidosis 
Deficient dietary intake Calcitonin 
Malabsorption Diuretics 
Celiac disease Glucocorticoids 
Crohn’s disease Bicarbonate 
Gastrectomy  
Pancreatitis  
Chronic diarrhea  
Chronic liver disease  
Chronic renal disease  
Vitamin D receptor defects  









Figure 3 Downstream Physiological Effects of Metabolite Deficiency. Vitamin D or 
calcium deficiency leads to decreased serum calcium levels, which results in increased 
PTH levels. Increased PTH leads to calcium reabsorption in the kidney to correct 
abnormally low serum calcium levels. Additionally, PTH increases urinary phosphate 
excretion, resulting in a decrease in serum phosphate levels. Decreased calcium-
phosphate levels cause defective bone mineralization, which leads to rickets and 
osteomalacia (Holick, 2006). 
 
As mentioned earlier, decreased levels of vitamin D or calcium can result in lower 
serum calcium levels, resulting in increased PTH levels. Increased PTH levels 
subsequently promote calcium reabsorption in the kidney in an effort to correct the 
abnormally low serum calcium levels. Furthermore, PTH will also increase urinary 
phosphate excretion, resulting in decreased serum phosphate levels. These actions 
together cause a decrease in the calcium-phosphate levels which contribute to defective 
bone mineralization and eventually leads to rickets and osteomalacia (Holick, 2006). 
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 There are three types of rickets: nutritional rickets, vitamin D-dependent rickets 
(VDDR), and vitamin D-resistant rickets (VDRR) (Rosen, & Bouillon, 2013). Nutritional 
rickets results from either inadequate sunlight exposure or inadequate dietary intake of 
vitamin D, calcium, or phosphate (Nield, Mahajan, Joshi, & Kamat, 2006). Nutritional 
rickets is most prevalent between the ages of three and 18 months (Salimpour, 1975). 
Additional factors shown to play an important role in the pathogenesis of nutritional 
rickets at this age range include solely breast-feeding, maternal vitamin D deficiency, 
living in temperate climates, lack of sunlight exposure, and darkly skin pigmentation 
(Atiq, Suria, Nizami, & Ahmed, 1998; Bassir et al., 2001). Clinical symptoms leading to 
the diagnosis of nutritional rickets include short stature, abnormal walking gait, and 
tetany, which are seizures or involuntary muscle contractions caused by increased action 
potential frequency of muscle cells due to hypocalcemia (Weisberg, Scanlon, Li, & 
Cogswell, 2004). Treatment of nutritional rickets includes increased sun exposure, 
correction of vitamin D insufficiency in diet, and in some cases dietary calcitriol, 
calcium, and phosphate supplements. 
 There are two forms of VDDR caused by genetic defects in the vitamin D 
pathway: vitamin D-dependent rickets type I (VDDR-I) and vitamin D-dependent rickets 
type II (VDDR-II). VDDR-I is a result from a defect in the Cyp27b1 gene, which 
encodes the production of 1α-hydroxylase (Carpenter, T.O., 1997). This defect causes the 
downregulation of Cyp27b1, resulting in low calcitriol levels. Additional characteristics 
of VDDR-I are normal calcifediol levels, elevated PTH levels, and low serum calcium 
(hypocalcemia). VDDR-II is caused by mutations in the VDR gene, which alter and 
prevent the VDR protein from interacting with calcitriol. By preventing the activation of 
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VDR through direct interaction with calcitriol, VDR is unable to bind to regulatory 
regions of target genes, where it acts to nucleate the formation of large protein complexes 
that are essential for directed changes in transcription (Pike & Meyer, 2010). As a result, 
VDR cannot regulate gene activity, often resulting in elevated calcitriol levels (Takeda, 
Yamamoto, Taketani, & Miyamoto, 1997).  
Symptoms of both VDDR forms begin to manifest between the ages of six 
months and 24 months, and these symptoms include leg bowing, osteomalacia, muscle 
weakness, bone pain, delayed growth, bone fractures, low serum calcium (hypocalcemia), 
low serum phosphate (hypophosphatemia), secondary hyperparathyroidism, and 
widening of bone ends (metaphysis) in the knees, wrists, and ribs (Takeda, Yamamoto, 
Taketani, & Miyamoto, 1997). Treatment for both forms of VDDR include dietary 
calcitriol, calcium, and phosphate supplements (Rosen, & Bouillon, 2013). 
 VDRR is primarily characterized by the ineffectiveness of vitamin D treatment to 
correct rickets. Clinical symptoms of VDRR include short stature, leg bowing, and dental 
abnormalities, which can be seen within months following birth but can also develop later 
in adolescence and adulthood (Nield et al., 2006). Leg bowing, which is the primary 
clinical symptom of rickets, is further exacerbated in children during weight bearing 
activities, such as walking. VDRR was first described in 1937 by Fuller Albright, an 
endocrinologist at Massachusetts General Hospital, based on his 4-year study of a patient, 
who displayed an unusual presentation of rickets characterized by high urinary calcium 
and phosphate excretion (Levine, Kleeman, & Felsenfeld, 2009). Vitamin D treatment 
failed to increase the absorption of calcium and phosphate in the patient, and treatment 
with parathyroid (PTH) extract failed to increase calcium absorption. Further insight into 
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patients with similar symptoms revealed low serum phosphate concentration as a 
common factor, coining the term hypophosphatemic rickets. 
Hypophosphatemic Rickets 
 Hypophosphatemic rickets is characterized by hypophosphatemia (Cho et al., 
2005). There are three primary mechanisms for which hypophosphatemia can arise: 1) 
redistribution of phosphate from extracellular fluids into cells, 2) decreased intestinal 
absorption, and 3) renal phosphate wasting as characterized by increased phosphate levels 
in urine (Liamis, Milionis, & Elisaf, 2010). Since the discovery of VDRR, several forms 
of hypophosphatemic rickets have been identified, most of which are distinguished by 
their patterns of inheritance and genetic cause, which are summarized in Table 2.  
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Table 2 List of known disorders of renal phosphate wasting diseases and their accompanying biochemical profiles 





Tumor-induced osteomalacia Mesenchymal tumor Ectopic, unregulated production of FGF23 and 
phosphatonins sFRP4, MEPE, FGF7 
Low Normal Normal or high 
X-linked hypophosphatemia PHEX mutation Inappropriate FGF23 synthesis from bone Low Normal Normal or high 
Autosomal dominant 
hypophosphatemic rickets  
FGF23 mutation Increased circulating intact FGF23 caused by 
mutations that render it resistant to cleavage 
Low Normal Normal or high 
Hereditary hypophosphatemic 
rickets with hypercalciuria 
SLC34A3 mutation Loss of function NaPiIIc mutations resulting in renal 
phosphate wasting without defect in 1,25(OH)2D3 
synthesis 
Low High Low or normal 
Autosomal recessive 
hypophosphatemic rickets Type 
1 
DMP1 mutation Loss of DMP1 causes impaired osteocyte 
differentiation and increased production of FGF23 
Low Low or normal Normal 
Autosomal recessive 
hypophosphatemic rickets Type 
2  
ENPP1 mutation  Increased production of FGF23 Low Low or normal High 
Hypophosphatemic rickets  with 
hyperparathyroidism 
αKlotho translocation Increased KLOTHO, FGF23, and downstream FGF23 
signaling 
Low Unknown High 
Fibrous dysplasia GNAS mutation Increased FGF23 production from the dysplastic bone Low Low or normal High 




Increased FGF23 production from the dysplastic bone 
and from the nevi 
Low Unknown High 




SLC34A1 mutation Renal phosphate wasting without a defect in 
1,25(OH)2D3 synthesis 




SLC9A3R1 mutation Renal phosphate wasting through potentiation of PTH-
mediated cAMP production 
Low Unknown Unknown 
Fanconi renotubular syndrome 
Type 2 
SLC34A1 mutation Renal phosphate wasting without a defect in 
1,25(OH)2D3 synthesis 
Low Low, normal, 
or high 
Unknown 
Tumoral calcinosis KL mutation Unknown High Normal or high Low 
Hyperphosphatemia syndrome e FGF23 or GALNT3 
mutation 
Unknown High Normal or high High 
Rosen, & Bouillon, 2013
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The list of currently known renal phosphate wasting disorders is significant 
because roughly 50% of these disorders share a similar biochemical profile of low serum 
phosphate, low-to-normal serum calcitriol, and normal-to-high serum FGF23, despite 
their various genetic defects. Of the disorders listed in Table 2, this review will discuss 
further the more common forms of renal phosphate wasting disorders that lead to 
hypophosphatemic rickets: tumor-induced osteomalacia, X-linked hypophosphatemia, 
and autosomal dominant hypophosphatemic rickets. 
 Tumor-induced osteomalacia (TIO), or oncogenic osteomalacia, is an acquired 
paraneoplastic syndrome of renal phosphate wasting (Rosen, & Bouillon, 2013). The 
most commonly associated tumors that cause TIO are a benign mesenchymal or mixed 
connective tissue tumor (Zadik & Nitzan, 2012). These tumors occur equally in both soft 
tissue and bone, and they are characterized by an admixture of spindle cells, osteoclast-
like giant cells, prominent blood vessels, cartilage-like matrix, and metaplastic bone. 
These tumors ectopically express and secrete FGF23, which as mentioned earlier 
promotes urinary phosphate excretion (De Beur et al., 2002). TIO symptoms include 
bone pain, muscle weakness, gait abnormalities, hypophosphatemia, multiple bone 
fractures, height loss, and generalized debilitated status (Hautmann, Hautmann, Kolbl, 
Herr, & Fleck, 2015).  
Figure 4 highlights the clinical features of TIO, which include height loss, 
excessive outward curvature of the spine (kyphosis), and pectus carinatum (pigeon chest) 
(Chong, Molinolo, Chen, & Collins, 2011). Additional symptoms that require either 
clinical or radiographic identification are bone pain, muscle weakness, and multiple bone 
fractures (Jan de Beur, S M, 2005). Although TIO is not considered fatal, the physical 
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abnormalities significantly impact the quality of life of patients. Furthermore, the length 
of time from onset of symptoms until diagnosis is often prolonged due to a lack of 
knowledge regarding disease existence. 
 
Figure 4 Clinical effects of advanced tumor-induced osteomalacia (TIO). The gowned 
patient in picture A is standing next to his father who does not have TIO. The patient was 
reported to be previously taller than his father. Picture B demonstrates kyphosis and 
pectus carinatum (pigeon chest), which is a result from multiple compression fractures 
due to osteomalacia. Pictures of the father and patient are reproduced with their 
permission (Chong et al., 2011). 
 
For TIO, the detection and resection of the primary tumor are curative and can 
often lead to rapid resolution of the patient’s symptoms (Chong et al., 2011). However, 
these tumors are often small, slow growing, and found in various locations throughout the 
body, such as sinuses, long bones, distal extremities, and the groin, making it difficult to 
detect and diagnose. A complete physical examination is required to assess palpable 
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tumor masses in subcutaneous tissues (Rosen, & Bouillon, 2013). In some cases, excision 
may not be possible and this largely depends on the size and location of the tumors. 
While TIO symptoms rapidly resolve if the causal tumors can be resected, there 
are cases in which tumor resection is not feasible or recurrence of the tumor occurs after 
resection (Chong et al., 2011). In patients for non-excisable tumors, the current standard 
of care is oral phosphate and calcitriol replacement. The goal of this oral phosphate is to 
replace ongoing renal phosphate loss, and the calcitriol supplements replace insufficient 
renal production of calcitriol to enhance renal and gastrointestinal phosphate 
reabsorption. Treatment efficacy is limited as it does not treat the underlying cause of the 
disease and its benefits must be balanced with monitoring for potential risks, which 
include elevated serum calcium levels (hypercalcemia), the deposition of calcium oxalate 
and calcium phosphate in the kidney (nephrocalcinosis), and the formation of kidney 
stones (nephrolithiasis) (Zadik & Nitzan, 2012). 
Another prominent form of hypophosphatemic rickets is X-linked 
hypophosphatemia (XLH), which is the most common renal phosphate wasting disorder 
affecting approximately one in 20,000 individuals (T. O. Carpenter, Imel, Holm, Jan de 
Beur, & Insogna, 2011). It is an X-linked dominant form of rickets or osteomalacia and 
leads to bone deformity resulting in short stature and bowed legs due to increased levels 
of osteoid. XLH is caused by a mutation in the phosphate-regulating endopeptidase 
(PHEX) gene. PHEX is a member of the M13 family of neutral endopeptidases that is 
expressed by osteoblasts and osteocytes. PHEX is expressed in late embryonic 
development as skeletal mineralization begins (Ruchon et al., 1998). Table 3 illustrates 
the research findings leading to the discovery of the PHEX mutation.  
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Table 3 Timeline of XLH pathophysiology discoveries 
Date Finding Reference 
Discovery, clinical presentation, and treatment of rickets 
1645 First published description of rickets O'Riordan & Bijvoet, 
2014 
1728 Publication on the effectiveness of shark 
liver ointment treatmet 
Johnstone, Smellie, 
Balfour, Balfour, & 
Robertson, 1779 
1890 Identification of correlation between 
increased geographical distribution of 
rickets and locations with decreased 
sunlight 
Chesney, 2012 
1917 Initial use of ultraviolet light treatment Wacker & Holick, 2013 
1922 Publication suggesting the existence of a 
vitamin which promotes calcium deposition 
McCollum et al., 2002 
1937 First description of vitamin D resistant 
rickets 
Choudhury, Jebasingh, 
Ranabir, & Singh, 2013 
Genetics 
1958 Established as X-linked disorder Francis, F., et al., 1995. 
1959 Existence phosphate-regulating hormone 
(eventually found to be FGF23) causes 
acquired rickets in a child cured by 
excision of a bone-derived tumor  
Prader, A., et al., 1959. 
1972 Inborn error of phosphate transport White, K.E., et al., 2000. 
1976 Hyp mouse model of XLH discovered Eicher, E.M., et al., 1976. 
1995 XLH as a result of mutation in PHEX gene Francis, F., et al., 1995. 
2000 Mutation in FGF23 at a pro-protein 
convertase consensus site is cause of 
ADHR 
White, K.E., et al., 2000. 
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XLH as a result of a circulating factor 
1974 Transplantation of normal kidney into 
patient with XLH did not reverse the 
phosphaturia 
Morgan, J.M., et al., 
1974. 
1989 Parabiosis of Hyp and normal mice: normal 
mice phosphaturic 
Meyer, R.A., et al., 1989. 
1992 Cross-transplantation studies: Hyp mouse 
defect not intrinsic to kidney 
Nesbitt, H., et al., 1992. 
1996 Serum from Hyp mouse inhibits phosphate 
uptake by mouse proximal tubule cells in 
culture 
Nesbitt, H., et al., 1992. 
Abnormal Vitamin D metabolism 
1982 Serum calcitriol levels inappropriately 
normal in XLH 
Lyles, K.W., et al., 1982. 
2003 1α hydroxylase activity blunted in Hyp 
mouse in response to a decrease in dietary 
phosphate or to PTH 
Fujiwara, I., et al., 2003. 
Role of FGF23 in hypophosphatemia 
2002 Infusion of recombinant FGF23 or 
overexpression of FGF23 results in 
enhanced renal phosphate excretion and 
hypophosphatemia 
Tenenhouse, H.S., 1999. 
2003 FGF23-neutralizing antibodies normalize 
serum phosphate and calcitriol in Hyp 
mouse 
Aono, Y., et al., 2003. 
2003 FGF23 levels are elevated in many patients 
with XLH 
Jonsson, K.B., et al., 
2003. 
2004 Targeted ablation of the FGF23 gene leads 
to hypophosphaturia and 
hyperphosphatemia 
Sitara, D., et al., 2004. 
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2004 FGF23 inhibits renal proximal tubule 
phosphate reabsorption via suppression of 
the NaPi type IIa transporter activity 
Shimada, T., et al., 2004. 
2004 FGF23 administration lowers calcitriol 
levels, suppresses 1α hydroxylase activity, 
and stimulates 24-hydroxylase activity 
Shimada, T., et al., 2004. 
2006 FGF23 levels are elevated in Hyp mouse Liu, S., et al., 2006. 
2006 Klotho regulates FGF23 signaling Kuro-o, M., 2006; 
Kurosu, H., et al., 2006. 
 
The discovery of the hypophosphatemia (Hyp) mouse model, which has a large 
portion of the PHEX gene deleted, was of great importance for advancing XLH research 
because the mutant mice displayed similar XLH clinical symptoms including 
hypophosphatemia, bone changes resembling rickets, dwarfism, and increased excretion 
of phosphate anion by low net tubular reabsorption (Eicher, Southard, Scriver, & 
Glorieux, 1976). The Hyp mouse model has also aided the advancement of methods for 
identifying and treating the underlying cause of XLH, such as the role of FGF23 as a 
diagnostic marker and treatment target. Table 3 highlights that further research is needed 
to identify a treatment for the underlying cause of XLH.  
Clinical manifestations of XLH typically vary in severity, however most pediatric 
patients show leg deformities and bowing. Progressive bowing, more specifically antero-
medial rotational tibiae torsion, and short stature are the typical skeletal outcome in 
untreated children. Medical therapy in the form of oral phosphate and active vitamin D 
treatment can improve these symptoms; however, symptoms often are not completely 
resolved with currently available therapies.  
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Autosomal dominant hypophosphatemic rickets (ADHR) is a rare form of 
hypophosphatemic rickets caused by FGF23 mutations (Econs, McEnery, Lennon, & 
Speer, 1997). Although clinical and biochemical findings are similar to those seen in 
XLH during childhood, there are instances of delayed onset of clinical symptoms and, in 
rare cases, resolution of phosphate wasting (Imel et al., 2011). The differences between 
the two disorders are more noticeable in adulthood because adults with ADHR are less 
likely to display lower extremity deformities, which may be a result of proper growth 
plate fusion prior to the onset of renal phosphate wasting. Similar to XLH, ADHR 
treatment includes oral phosphate and calcitriol. 
Clinical Presentation of Hypophosphatemic Rickets 
 Patients with hypophosphatemic rickets are typically born with low-to-normal or 
normal levels of serum phosphate, normal bone length, and no skeletal abnormalities on 
radiographs (Rosen, & Bouillon, 2013). However, the serum phosphate levels decrease 
over time leading to rickets. In addition to hypophosphatemia, affected children also have 
low-to-normal serum calcitriol concentrations, elevated ALP levels, normal serum 
calcium, normal PTH, and normal calcifediol (Carpenter et al., 2011).  
 Clinical manifestations of hypophosphatemic rickets vary in severity, but most 
children display poor growth and lower extremity bowing deformities (Rosen, & 
Bouillon, 2013). Once infants begin to bear weight on their legs, the compromised 
skeletal tissue succumbs to bowing genu valgum (knocked knees). The combination of 
height loss caused by the bowing of the legs and the growth plate defects can lead to a 
permanent loss of growth potential despite the fact that children with hypophosphatemic 
rickets experience a normal pubertal growth spurt (Carpenter et al., 2011). The growth 
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plate, also known as the epiphyseal plate or physis, is the area of growing tissue near the 
ends of the long bones in children and adolescents. Once growth is completed, typically 
in adolescence, the growth plates close and are replaced by solid bone. Once growth 
plates close, the hypophosphatemia and lower extremity deformities remain throughout 
adulthood. These structural deformities can lead to gait abnormalities, osteoarthritis, joint 
pain, stiffness, tendon and ligament calcification (enthesopathy), increased bone fragility, 
and dental abscesses (Carpenter et al., 2011; Reid et al., 1989). 
Treatment of Hypophosphatemic Rickets 
The primary goals of hypophosphatemic rickets treatment for children are to 
correct or minimize rickets, osteomalacia, radiographic abnormalities, and skeletal 
deformities, while in adults, the goals are to reduce pain and osteomalacia as well as 
improve fracture healing (Carpenter et al., 2011). The differences in treatment goals 
between children and adults is due to the fact that treatment during growth, specifically 
prior to growth plates closure, can partially correct leg deformities and lower the number 
of expected surgeries in adulthood along with optimizing adult height (Carpenter et al., 
2011). 
The current standard of care treatment for pediatric hypophosphatemic rickets 
patients consists of oral phosphate and high-dose calcitriol (Carpenter et al., 2011). 
Treatment begins with lower doses to avoid gastrointestinal side effects, and doses are 
eventually titrated to a weight-based dose of calcitriol at 20 to 30 ng/kg/day along with 
phosphate at 20 to 40 mg/kg/day administered in three to five times a day (Carpenter et 
al., 2011). Due to the lack of standardization for hypophosphatemic rickets treatment, it is 
at the clinician’s discretion to administer higher doses of phosphate for up to a year. The 
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high-dose phosphate treatment consists of calcitriol at 50 to 70 ng/kg/day along with 
phosphate at 20 to 40 mg/kg/day (Carpenter et al., 2011). In adulthood, patients may be 
treated with lower calcitriol and phosphate doses; however, it is currently unclear if 
patients require long-term treatment or whether the treatment can be discontinued. Most 
hypophosphatemic rickets studies do not report weight-based calcitriol and phosphate 
treatment and when dosing is reported, the values can vary widely from 10-80 ng/kg/day 
of calcitriol and 30-180 mg/kg/day for phosphate, suggesting uncertainty of optional 
doses (Carpenter et al., 2011). Since oral phosphate and calcitriol therapy is weight-
based, not reporting weight-based treatments across institutions inhibits the development 
of a standardized treatment regimen. 
Because over treatment of phosphate can lead to hyperphosphatemia, 
hypercalcemia, hypercalciuria, hyperparathryodisim, and nephrocalcinosis, laboratory 
monitoring at three-month intervals is necessary to measure serum phosphate, serum 
calcium, serum creatinine, urinary calcium, urinary creatinine, and overall renal function 
in order to properly adjust treatment and avoid any complications (Carpenter et al., 2011). 
Treatment endpoints to measure therapeutic response include measuring height, the 
degree of skeletal deformity, and epiphyseal healing by radiographic imaging. 
 When successful, standard of care treatment can lead to improved growth, though 
still not normal, and moderate resolution of rickets as seen in radiographs.  In order to 
successfully evaluate rickets severity, radiographic assessment by X-ray or CT scan of 
the distal femoral tibial sites should be taken regularly in order to ensure epiphyseal 
correction; however, currently there is no standardization of X-ray frequency (T. 
Carpenter, 1997). X-rays are also used to assess the healing of rickets and evaluate 
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skeletal deformities for surgical management.  In adults, standard of care treatment is 
initiated in response to spontaneous fractures, skeletal pain, and osteomalacia. Treatment 
of these symptoms may eventually lead to symptom resolution; however, this approach 
can take several months before fractures fully heal and skeletal pain subsides. In some 
cases, surgical intervention may be required to correct skeletal deformities. The goals of 
hypophosphatemic rickets surgery include straightening or partial correction of bowed 
legs and gait improvement (Carpenter et al., 2011). Forms of surgery such as bone 
stapling and bone straightening by 8-plates can achieve leg straightening; however, the 
procedures are complicated by delayed bone healing in patients with hypophosphatemic 
rickets. 
Diagnosis of Hypophosphatemic Rickets 
A combination of clinical and biochemical measurements is used to correctly 
identify and treat hypophosphatemic rickets (Carpenter et al., 2011). As illustrated in 
Table 2, biochemical findings are, at times, indistinguishable from other various 
phosphate wasting diseases.  Diagnosis of renal phosphate wasting is typically measured 
by calculating the percent of tubular reabsorption of phosphate (TRP) and the renal 
tubular reabsorption of phosphate (TMP/GFR) by fasting urine sample collection 
(Carpenter, 1997). TRP is the percent of filtered phosphate reabsorbed by renal tubules. It 
is calculated only in the fasting state with the following formula (Eq. 1): 
Eq 1: 100 x [1- ((urine phosphate/urine creatinine) x (serum creatinine/serum 
phosphate))] 
A normal TRP percentage is between 85% and 95% when phosphate levels are normal 
(Chong et al., 2011). A reduced TRP in the presence of hypophosphatemia indicates renal 
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defect in phosphate reabsorption. TMP/GFR is the renal tubular maximum reabsorption 
rate of phosphate to glomerular filtration rate (GFR), which describes the flow rate of 
filtered fluid through the kidney (Payne, 1998a). It is calculated with the following 
formula (Eq. 2):  
Eq 2: TMP/GFR = phosphate plasma concentration – (urine phosphate 
concentration x creatinine plasma concentration / urine creatinine concentration) 
The ratio measures the maximum renal tubular phosphate reabsorption in mass per unit 
volume of glomerular filtrate. It is independent on the rate of phosphate flow into the 
extracellular space from the gut, cells and bones, and the glomerular filtration rate, both 
of which affect plasma phosphate concentration (Payne, 1998b). Age-based, normal 
TMP/GFR measured in mmol/L are: 1.55 to 2.97 for newborns; 1.07 to 2.23 for 1 month 
to 2 years old; 1.10 to 1.88 for 2 to 12 years old; 0.93 to 1.71 for 12 to 16 years old; and 
0.88 to 1.26 for 16 years old and older (Payne, 1998b). 
Of the types of hypophosphatemic rickets, distinguishing between them can be 
difficult because serum chemistries are identical in TIO, XLH, and ADHR as seen in 
Table 2. For all three diseases, serum phosphate levels are low, serum calcitriol levels are 
normal, and serum FGF23 levels are normal or high. The biochemical diagnosis of 
specific forms of hypophosphatemic rickets in infants can be difficult since phosphate 
levels are usually higher in infants than older children due to skeletal development and 
can be mischaracterized as normal phosphate levels (Carpenter et al., 2011). As a result, 
genetic testing for PHEX and FGF23 mutations can help correctly diagnosis the renal 
phosphate wasting disorder as XLH or ADHR, respectively. In most cases, XLH first 
presents in early childhood, while ADHR can present in either childhood or adulthood 
 26 
 
which may help identify the cause of renal phosphate wasting (Econs & McEnery, 1997). 
However, biochemical findings alone are not sufficient to correctly diagnose 
hypophosphatemic rickets. As a result, biochemical measurements are typically 
complemented with a detailed review of the patient’s and patient’s family history, 
including a review of their growth chart (Carpenter et al., 2011). The focus of the family 
history review is to identify family members with short stature and bowed legs. 
In instances when hypophosphatemic rickets is correctly diagnosed and treatment 
begins, disease severity and treatment efficacy are measured by X-ray radiographic 
imaging (Carpenter et al., 2011). However, there is currently no adopted, standardized 
process for collecting and reviewing repeat X-rays. Furthermore, repeat X-ray imaging in 
patients leads to increased exposure to ionizing radiation and since pediatric patients are 
more sensitive to radiation than adults, increasing the patient’s cancer risk, 
hypohphosphatemic rickets pediatric patients are less likely to have repeat X-rays 
performed (Carpenter et al., 2011). 
Early diagnosis of hypophosphatemic rickets in infants is challenging when it is 
based solely on clinical features and biochemical findings (Pavone et al., 2015). 
Mutational analysis of the PHEX and FGF23 genes are available and can help; however, 
studies have shown that mutations can only be found in 50-70% of affected individuals 
(Ichikawa et al., 2007). Furthermore, mutational testing is expensive and often not 
covered by health insurance companies. Therefore, the goal of this literature review is to 
evaluate the evidence whether other methods can be used to supplement and improve 




Although there is a wealth of information on the disorders that cause 
hypophosphatemic rickets, challenges regarding the diagnosis and treatment of these 
disorders remain. The purpose of this targeted literature review is to determine if 
sufficient evidence exists to warrant the investigation or consideration of alternative 
biomarkers as clinical measurement tools to improve diagnosis of hypophosphatemic 
rickets. 
Osteopontin (OPN)  
Osteopontin (OPN), identified in 1985, is a non-structural protein found in the 
extracellular matrix (Franzén & Heinegård, 1985). It is a member of the small integrin-
binding ligand, N-linked glycoprotein (SIBLING) protein family. OPN is expressed by 
several cell types and tissues, including osteoblasts, osteocytes, fibroblasts, skeletal 
muscle, and the kidney (Chen et al., 2014; Xie, Singh, Siwik, Joyner, & Singh, 2003; 
Zanotti et al., 2011; Z. X. Zhang et al., 2010). A primary function of OPN is regulating 
bone mineralization. As a member of the SIBLING protein family, OPN can bind directly 
to specific hydroxyapatite crystals to inhibit bone mineralization. The formation of 
hydroxyapatite crystals is important for bone mineralization and makes up to 50% of the 
volume and 70% of the weight of human bone and provide the compressive strength of 
bone (Palmer, Newcomb, Kaltz, Spoerke, & Stupp, 2008). 
A clinical study in 2017 identified seven XLH patients with inactivating PHEX 
mutations and measured the expression levels of OPN at sites of defective bone 
mineralization. Results indicated that these XLH patients had increased levels of OPN in 
the bone matrix, along with an enlarged, hypomineralized, and defective pattern of 
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skeletal mineralization (Boukpessi et al., 2016). These findings suggest that increased 
levels of OPN expression near osteocytes correlates with defective bone mineralization 
sites in XLH patients, and that OPN expression can be used as a measurable biomarker in 
XLH clinical trials. Since the other known genetic biomarkers, FGF23 and PHEX, can 
only be found in 50-70% of individuals with XLH as noted previously, measuring OPN 
expression can be used as an additional genetic biomarker to help determine the specific 
cause of renal phosphate wasting (Boukpessi et al., 2016). 
In support of this, another study comparing OPN-deficient (OPN -/-) mice with 
wild type (OPN +/+) control mice demonstrated that OPN -/- mouse bones are more 
mineralized than their age, background, and sex-matched OPN +/+ counterpart animals 
(Pollack, Linnemeyer, & Gill, 1994). Whereas XLH patients displayed bone 
hypomineralization due to increased OPN expression in the aforementioned clinical 
study, OPN deficient mice display bone hypermineralization. Moreover, mineral 
maturity, as defined by mineral hydroxyapatite crystal size and perfection, was 
significantly increased throughout all observed anatomic regions of OPN-/- animals. The 
tibia and femur sections from 12-week-old and 16-week-old mice revealed that OPN -/- 
mice displayed fragile bone due to hypermineralization in the more mature areas of the 
central cortical bone (Pollack, Linnemeyer, & Gill, 1994). Since bone differences that 
exist between OPN -/- and OPN +/+ mice cannot be detected by conventional imaging 
used for humans, fourier transform infrared microspectroscopy (FT-IRM) and infrared 
imaging (FT-IRI) are used to characterize bone mineral in both mouse models (Boskey, 
Spevak, Paschalis, Doty, & McKee, 2002). FT-IRM is a physical-chemical technique that 
 29 
 
provides data on molecular structure at approximately 10 µm spatial resolution 
(Mendelsohn, Paschalis, & Boskey, 1999).  
Figure 5 is an image obtained by FT-IRI that shows the increased maturity of 
bone crystals in the absence of OPN. The red areas in Figure 5 indicate higher levels of 
phosphate ion (a component of hydroxyapatite crystals), which correlate with increased 
crystal size and perfection (Boskey et al., 2002). The observed changes in bone mineral 
are consistent with the observed in vitro effects of OPN, in which a purified OPN 
solution has been shown to be an effective inhibitor of hydroxyapatite crystal formation 






Figure 5 Mineralization and Crystallinity of Osteoponin-Deficient Mice. FT-IRI of 
mineral-to-matrix ratio in long bones of a OPN-deficient mouse (KO; OPN-/-) and an age-
matched and background-matched wild type mouse (WT; OPN+/+). These are typical 
images of mineral-to-matrix ratio in the cortices of the knockout (KO) mouse and wild type 
(WT) mouse at 16 weeks of age. The red areas indicate higher levels of phosphate ion, 
which correlate with increased hydroxyapatite crystal size and perfection. The bone 
mineral changes observed are consistent with in vitro effects of OPN indicating that OPN 
solution purified from bone is an effective inhibitor of hydroxyapatite crystal formation 
and growth. The top image displays the raw data expressed as the integrated area of 
phosphate bands. The middle image displays the mineral-to-matrix ratio. The bottom image 




A disadvantage to the current standard of care treatment for hypophosphatemic 
rickets is acute kidney injury as a result of nephrocalcinosis, a disorder in which there is 
increased calcium deposited in the kidneys (Carpenter et al., 2011). As previously 
mentioned, one of the goals of oral phosphate and calcitriol treatment is to normalize 
serum phosphate levels, which requires careful monitoring to avoid phosphate overdose, 
hypercalciuria with nephrocalcinosis, and renal insufficiency (Taylor, Sherman, & 
Norman, 1995). A clinical study revealed that 80% of hypophosphatemic rickets patients 
receiving standard of care treatment exhibited nephrocalcinosis as detected by 
ultrasonography (Kooh, Binet, & Daneman, 1994). Although OPN is produced by 
osteoblasts and is one of the most abundant non-collagenous bone proteins, high levels of 
OPN can be seen in the kidneys, specifically in the loop of Henle and the distal 
convoluted tubules during nephritis or inflammation of kidneys (M Giachelli et al., 1994; 
Sodek, Ganss, & McKee, 2000). While the role of OPN in cellular processes within the 
kidneys are not fully understood, research has shown that increased OPN expression by 
tubular epithelial cells promotes the development of renal ischemia reperfusion injury 
(IRI), which is characterized by reduced renal blood flow (Zhang et al., 2010). In IRI, 
natural killer cells, a type of cytotoxic lymphocyte critical to the innate immune system, 
migrate to the kidney and induce tubular epithelial cells apoptosis. Although the 
mechanism of natural killer cell migration and activation during IRI is still unknown, a 
study identified the following: 1) Tubular epithelial cells express high levels of OPN in 
vivo; and 2) OPN-deficient mice have reduced infiltration of natural killer cells and less 
kidney tissue damage when compared to wild-type mice (Zhang et al., 2010). Taken 
together, these results suggest that inhibiting OPN expression may preserve kidney 
 32 
 
function. A potential advantage of targeting and inhibiting osteopontin over the current 
standard of care treatment for hypophosphatemic rickets would then be the potential 
decrease in acute kidney damage. 
Currently there is one OPN inhibitor (brefelamide) which was used to inhibit 
OPN expression and function in A549 human lung carcinoma cells (J. Zhang et al., 
2016). As seen in Figure 6, A549 cells treated with increasing concentrations of 
brefelamide displayed lower OPN expression levels in comparison to the untreated 
control group (Zhang et al., 2016). Although brefelamide has not been tested in the 
clinical setting for bone mineralization disorders, it may represent a promising 
therapeutic modality for hypophosphatemic rickets and warrants further testing. 
 
Figure 6 Osteopontin Concentrations with Brefelamide Treatment. A549 cells were 
cultured in the absence or presence of various brefelamide concentrations. After 48 hours 
of culture, supernatant aliquots were analyzed by ELISA for OPN production. Cell counts 
were simultaneously measured with Cell Proliferation Reagent WST-1 for normalization. 
Normalized OPN secretion from the control group was set as 100%, and those from other 
brefelamide-treated groups were expressed as relative percentages. Results were presented 
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as the means ± standard deviations of three independent triplicate transfections. ** 
indicates P<1.01 versus the vehicle control (Zhang et al., 2016). 
 
The majority of current clinical trials treating patients with hypophosphatemic 
rickets do not analyze OPN expression. However, common endpoints for current 
hypophosphatemic rickets clinical trials do capture FGF23 and PHEX as biochemical 
biomarkers. A recommendation for future hypophophatemic rickets clinical trials and 
natural history studies is to include osteopontin analysis, which would provide additional 
data whether OPN can serve as a potential diagnostic biomarker and allow scientists and 
physicians to understand whether a correlation exist between OPN and renal phosphate 
levels and the severity of defective bone mineralization. 
Magnetic Resonance Imaging (MRI) 
 Diagnosis of hypophosphatemic rickets can prove difficult in the absence of a 
clinician with rare disease experience or a family member with a genetically confirmed 
diagnosis of a renal phosphate wasting disorder (Carpenter et al., 2011). In these 
instances, radiographic imaging of rickets can help identify and diagnose 
hypophosphatemic. X-rays and CAT (or CT) scans are forms of radiographic imaging 
that can reveal bone deformities and measure disease severity and treatment efficacy.  
Figure 7 shows the differences between radiographic bone features between a 
patient with XLH and one with no disease. In individuals without disease, the physis 
appears as a flat disc between the epiphysis and metaphysis, while the normal zone of 
provisional calcification (ZPC) is visualized as a continuous, thin band (Lempicki et al., 




Figure 7 XLH and normal radiographic patterns. (a) and (b) indicate routine radiograph of 
a healthy 9-year-old boy showing normal pattern of the left knee on a frontal plain 
radiograph (a) and a drawing (b). The physis (white arrows) appears as a radiolucent flat 
disc between the epiphysis and the metaphysis. The normal ZPC (arrowheads) is a 
continuous, regular, thin (<1 mm thick) radiodense band. (c) Frontal radiograph of a boy 
aged 3 years and 5 months treated for XLH. The ZPC (arrowhead) is ill defined, and the 
physis (solid, vertical line) is widened. Note the preserved cortical bone (black arrow) and 
the coarse trabecular bone (Lempicki et al., 2017). 
 
Both forms of radiographic imaging expose patients to radiation that can lead to 
tissue damage and increase the patient’s risk to cancer (Carpenter et al., 2011). This is 
especially true in children who are more sensitive to radiation than adults, especially 
considering that radiographs are often performed on a regular basis for patients with 
hypophosphatemic rickets (Lempicki et al., 2017). MRI is a form of imaging that uses 
strong magnetic fields and radio waves to produce detailed images of the body. Unlike X-
rays and CT scans, MRI scanners use powerful magnets to align water protons into one 
direction. A combination of distributed and received radio signals are used to capture an 
image of various body parts, including bones and joints. Since MRI scanners do not 
involve exposing the body to radiation, like X-ray and CT scanners, MRI provides a safer 
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means of imaging for individuals more vulnerable to radiation exposure, such as children 
with hypophosphatemic rickets. 
 A clinical study was performed in pediatric patients using MRI to describe 
features in hypophosphatemic rickets, specifically XLH, and identify correlations 
between these features and XLH severity. Disease severity was based on both clinical and 
laboratory markers. Twenty-seven pediatric patients with PHEX-confirmed XLH had 
their distal femur imaged by MRI, which was then correlated to height measurement, leg 
bowing, dental abscesses, and ALP concentration. The distal femur was chosen for 
imaging because clinical features of XLH are most prominent at the epiphysis. In order to 
be eligible for participation, patients were required to: 1) be under the age of 18 years; 2) 
be monitored at the same clinic (French Reference Center for Rare Disorders of Calcium 
and Phosphate Metabolism); 3) present with hypophosphatemic rickets due to XLH with 
a confirmed PHEX mutation; 4) currently receiving standard of care treatment; 5) consent 
to an MRI scan of the distal left femur (or, if not possible, the distal right femur); and 6) 
not require sedation for the MRI scan. Twenty-four of the 27 patients had a frontal 
radiograph of the distal left femur within 1 year of their MRI(Lempicki et al., 2017). The 
frontal radiographs were part of the participants’ standard follow up for XLH. 
 Results seen in Figure 8 display the comparison of X-ray and MRI radiographs in 
patients with XLH. X-ray and MRI examples of patients with XLH (a 13-year-old and 
11-year-old with XLH) show ill-defined ZPC and physis lines in the X-rays, whereas the 
MRI images enables precise analysis of the region due to presence of image 




(Figure 8 Radiographic and MRI patterns of XLH patients. a) MRI image and (b) 
radiograph of a 13-year-old boy treated for XLH. Both ZPC (arrowheads) and physis 
(arrows) appear less defined on the radiograph compared to the MRI. (c) MRI findings of 
an 11-year-old boy treated for XLH with an enlarged physis (thin arrow) and discontinuous 
and irregular ZPC (arrowhead). (d) In the same 11-year-old boy, note the abnormal 
epiphyseal abnormalities (thick arrows) and metaphyseal Harris lines (arrowhead), which 
are lines of increased bone density caused by bone-growth arrest. (e) and (f) indicate medial 
femoral osteochondritis (arrows) in an asymptomatic 13-year-old girl with XLH who 
displays round-shaped abnormal hyperintensity in the subchondral area (Lempicki et al., 
2017). 
 
Hyperintensity is a term used to describe regions of a MRI that appear lighter in 
color than the surrounding tissues, as most MRIs are black and white with shades of gray. 
If an abnormality is bright (white), it is referred to as hyperintense. If an abnormality is 
dark, it is described as hypointense. These images indicate that the MRI is a more precise 
tool, due to its better resolution and 3-dimensional acquisition, in comparison to the 
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standard radiography used for evaluating physeal widening. The results of the study 
demonstrated that 78% of MRI images displaying abnormal calcification of the distal 
femur correlated with abnormally elevated ALP levels, which is a well-established 
biochemical marker of XLH disease activity (Lempicki et al., 2017). However, because 
the primary objective of the study was to describe MRI findings in XLH, a comparison of 
ALP levels with X-rays were not performed. 
These findings conclude that MRI of the distal femur provides precise rickets 
patterns that are correlated with ALP, an established biochemical marker of the XLH, 
while avoiding radiation exposure by X-ray or CT and providing a new qualitative 
marker for measuring disease severity. However, MRI is not easily accessible at clinics 
that see patients with hypophosphatemic rickets due to the cost of the imaging equipment 
and trained personnel required. According to Healthcare Bluebook, the cost of an MRI of 
the knee can range between $1000 and $4000 as opposed to an X-ray of the knee, which 
can range from $80 to $400. Furthermore, MRI image acquisition takes approximately 30 
minutes. As a result, sedation is often required in children, which may prevent its routine 
use throughout childhood follow-ups. 
Anti-FGF23 Targeted Therapy 
 Despite the benefits of oral calcitriol and phosphate as the standard of care 
treatment for hypophosphatemic rickets, it offers limited treatment efficacy, is 
inconvenient to administer for the patient, and requires regular monitoring by a physician 
for potential toxicities in patients (Carpenter et al., 2011). Furthermore, administration of 
oral calcitriol and phosphate can be associated with several adverse events such as 
hypercalcemia, hypercalciuria, and nephrocalcinosis (Fukumoto, 2018). As previously 
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mentioned, XLH is caused by inactivating mutations in the PHEX gene. In the absence of 
PHEX, the release of FGF23 by osteocytes is increased, which leads to increased renal 
phosphate excretion, decreased calcitriol production, and decreased intestinal absorption 
of calcium and phosphate (Carpenter et al., 2011). Because of its role in the development 
of hypophosphatemic rickets, FGF23 has been identified as a therapeutic target for 
patients with hypophosphatemic rickets. 
Pre-clinical evidence has demonstrated that increased FGF23 activity is the 
underlying pathogenesis of FGF23-related hypophosphatemic rickets (Yamazaki et al., 
2008). In an effort to confirm the effects of anti-FGF23 treatment in the pre-clinical 
setting, two mouse anti-FGF23 antibodies (FN1 and FC1) that recognize the N- and C-
terminal regions of FGF23, respectively, were developed. Two groups of 12-week-old 
male BALB/c mice were treated with either FN1 or FC1. Seven-week-old male Sprague-
Dawley rats treated with phosphate buffered saline were used as the control group. Blood 
serum was taken from each group at various time points from 1 hour-post treatment and 
36 hours post-treatment. FN1 and FC1 administration caused marked increases in serum 
phosphate and calcitriol levels in the BALB/c mice compared to the Sprague-Dawley rats 





Figure 9 Neutralizing activity of FN1 or FC1 in vivo. Time course of changes in serum 
parameters after a single administration of FN1, FC1, or phosphate buffered solution 
(PBS). Mice were killed at every time point for each treatment group to collect blood 
samples. The results represent means ± SE (N = 5). (b) p < 0.01 vs PBS-treated group at 
each time point (Yamazaki et al., 2008). 
 
The FN1 and FC1 antibodies were also tested in the Hyp mouse model, which 
showed increased serum phosphate and calcitriol levels (Aono et al., 2009). In a single 
dose preclinical study, 4 mg/kg (2 mg/kg of FN1 and 2 mg/kg of FC1) of anti-FGF23 
antibodies were administered subcutaneously into 6 to 8 weeks-old male Hyp mice and 
normal, wildtype mice. Another group of Hyp and wildtype mice were treated with 16 
mg/kg (8 mg/kg of FN1 and 8 mg/kg of FC1) of anti-FGF23 antibodies. As a control 
group, Hyp mice were treated with 16 mg/kg of an isotype-matched control antibody, 
thrombopoietin (TPO). Serum phosphate and calcitriol levels were measured over a 14-
day period. Hyp mice treated with 4 mg/kg of anti-FGF23 antibody had serum phosphate 
and calcitriol levels of 7.6 ± 0.4 mg/dl and 1007 ± 19 pg/ml, respectively. Hyp mice 
treated with 16 mg/kg of anti-FGF23 antibody had serum phosphate and calcitriol levels 
of 11.6 ± 0.9 mg/dl and 901 ± 25 pg/ml, respectively. Normal mice treated with anti-
FGF23 antibodies had serum phosphate and calcitriol levels of 7.6 ± 0.3 mg/dl and 139 ± 
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14 pg/ml, respectively. Hyp mice treated with TPO had serum phosphate and calcitriol 
levels of 5.1 ± 02 mg/dl and 137 ± 8, respectively (Aono et al., 2009). Therefore, results 
of the pre-clinical study indicate that a single subcutaneous injection of anti-FGF23 
antibodies succeeded in increasing serum phosphate and calcitriol levels in Hyp mice. 
Repeat injections of anti-FGF23 antibodies were also performed to observe the 
potential therapeutic benefit as defined by improved skeletal development in anti-FGF23 
antibody-treated Hyp mice. Hyp mice began treatment (4 or 16 mg/kg) at four weeks of 
age, which continued weekly for one month for a total of five doses (Figure 10). 
Compared to the untreated control mice, the treated Hyp mice displayed improved 
elongation of the femoral and tibial bones. Additionally, anti-FGF23 antibody treatment 
alleviate the enlarged epiphyses, which is typically observed in Hyp mice bones. Anti-
FGF23 antibody treatment improved skeletal development in Hyp mice, and these results 
suggest that FGF23 inhibition may improve biochemical and clinical abnormalities of 




Figure 10 Radiographs of Mice After Fibroblast Growth Factor 23 Treatment. Beneficial 
effects of repeated injections of FGF23 antibodies (FGF23Ab) on long bones in Hyp mice. 
Human anti-FGF23 antibodies were subcutaneously administered to two Hyp mouse model 
groups (4 mg/kg or 16 mg/kg) at 4 weeks of age (day 0), followed by four subsequent 
injections on days 7, 14, 21, and 28. Representative radiographs of femurs and tibias from 
three separate mice isolated after 31 days following treatment (Aono et al., 2009). 
 
 KRN23 is an investigational human monoclonal immunoglobulin 1 antibody 
targeted against FGF23 and is currently being studied in clinical trials (Aono et al., 
2009). A phase 2 open-label, dose-escalation trial of adults with XLH was conducted to 
measure if monthly KRN23 treatment would safely improve serum phosphate levels. The 
purpose of a phase 2 trial is to measure the efficacy and side effects of an investigational 
drug. An open-label trial is a clinical trial in which both the researchers and participants 
know which treatment is being administered.  
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Twenty-eight adults with XLH participated in a 4-month dose-escalation study 
with the option to continue into a 12-month extension study. The initial dose was 0.05 
mg/kg and would be increased to 0.1, 0.3, then 0.6 mg/kg over the course of the 4-month 
study. KRN23 doses were increased if the participant’s serum phosphate level were 
below the normal range and deemed safe by the treating investigator. If appropriate, the 
KRN23 dose would be increased to 1.0 mg/kg during the 12-month extension study based 
on serum phosphate levels. KRN23 was injected subcutaneously once every 28 days. The 
primary objective of the clinical trial was evaluated by measuring the proportion of 
subjects who achieved maximum serum phosphate levels within the normal range (>2.5 
to ≤4.5 mg/dL) (Imel et al., 2015). Serum phosphate ranges were defined as: less than 
normal (≤2.5 mg/dL), lower half of the normal range (>2.5 to ≤3.5 mg/dL), upper half of 
the normal range (>3.5 to ≤4.5 mg/dL), and above the normal range (>4.5 mg/dL) (Imel 
et al., 2015). 
Out of the 28 participants who received KRN23 treatment during the dose-
escalation study, 26 subjects received all four doses. Out of these 26 participants, 22 
participants entered the extension study and 19 received all 16 doses of KRN23. Two 
subjects withdrew during dose escalation, and three withdrew during the extension for 
unspecified reasons. After each dose of KRN23 during the dose-escalation study, the 
mean serum phosphate peaked by day 7, decreasing to a trough on day 28 (Figure 11). 
After each of the four escalating doses, peak serum phosphate was within the normal 





Figure 11 Effect of KRN23 on Serum Phosphate in Adults with XLH. Effect of KRN23 
on serum phosphate (Pi) in adults with XLH. KRN23 administration (arrow) occurred 
every 28 days. Data are presented as mean ± SD. *, P values remaining <0.05 were 
considered significantly different from the baseline values, which were recorded prior to 
beginning KRN23 treatment. An asterisk over a horizontal line with arrowheads indicates 
that all values shown under that line were different from baseline (P < 0.05). The 
horizontal broken lines indicate baseline level. The vertical broken lines separate the 4-
month dose-escalation study from the 12-month extension study; n = 28 for the dose-
escalation study; n = 22 for the extension study (Imel et al., 2015). 
 
Results from the dose-escalation study indicate that serum phosphate levels 
increased after each successive dose with the peak level reaching 3.0 ± 0.4 mg/dL after 
the fourth dose. During the 12-month extension study, 88.5% of the extension study 
participants reached a peak serum phosphate within the normal rangeAdditionally, 42.9% 
of the extension study participants maintained a normal serum phosphate level through 
the trough levels. Furthermore, serum phosphate did not exceed normal levels in any 
participant (Imel et al., 2015).  These studies indicate that KRN23 treatment in adults 
with XLH can result in improved serum phosphate. Thus, KRN23 shows a strong 
potential for improving an important biochemical outcome for patients with 
hypophosphatemic rickets. However, further studies are required to demonstrate whether 
KRN23 improves bone mineralization.  
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Discussion and Conclusion 
 Hypophosphatemic rickets is a rare disease that is a result of various phosphate 
wasting diseases, many of which have similar clinical and biochemical profiles. Coupled 
with low disease prevalence and a lack of understanding of the underlying disease 
pathogenesis for each phosphate wasting disorder, hypophosphatemic rickets continues to 
be difficult to diagnose and treat.  
Despite the limitations of current diagnostic tools and standard of care therapy for 
hypophosphatemic rickets, this targeted literature review has yielded potential directions 
for new disease biomarkers and treatments. OPN, a protein primarily expressed in bone 
and kidney, is a known regulator of bone mineralization and is expressed at high levels at 
sites of defective bone mineralization. Although current clinical trials for 
hypophosphatemic rickets collect data on other known genetic biomarkers associated 
with hypophosphatemic rickets, such as FGF23 and PHEX, they do not measure OPN 
expression in the clinical setting but should be considered for future trials. The 
availability of brefelamide, an OPN inhibitor currently being used in preclinical trials, 
presents a future application for OPN as a therapy for hypophosphatemic rickets.  
Additionally, MRI as a clinical tool for measuring disease severity and treatment 
efficacy shows a clear advantage over X-ray imaging, which is the current standard. 
Specifically, MRI is demonstrated to be a more precise tool in comparison to the standard 
radiography used for assessing rickets and poor bone mineralization severity. 
Furthermore, MRI scanners do not expose individuals to radiation, thereby providing a 
safer means of imaging for individuals more vulnerable to radiation exposure. 
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Lastly, findings from the KRN23 clinical trials show that anti-FGF23 therapy can 
improve serum phosphate levels, which is an important biochemical outcome 
measurement for patients with hypophosphatemic rickets. Because KRN23 currently 
shows biochemical improvement in adults with XLH, its application in various renal 
phosphate wasting disorders and pediatric populations are potential directions for future 
hypophosphatemic rickets research. 
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